{"id":904546,"date":"2025-11-03T17:11:41","date_gmt":"2025-11-03T22:11:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/"},"modified":"2025-11-03T17:11:41","modified_gmt":"2025-11-03T22:11:41","slug":"3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/","title":{"rendered":"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025"},"content":{"rendered":"
\n

COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9.<\/p>\n\n\n
Thursday
November 6
10 a.m. \u2013 12 p.m.
Convention Center
Exhibit Hall<\/td>\n		\n Abstract<\/a>\u00a0and Poster #TH-PO0227<\/p>\n

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 3-Year Results from the PaTH Forward and PaTHway Trials<\/strong><\/p>\n

Gosmanova, Schwarz,<\/em>Rejnmark et al<\/em>
Presentation on November 6 by Dr. Elvira Gosmanova<\/em><\/p>\n

The abstract is also available in the Journal of the American Society of Nephrology <\/em>36(10S):10.1681\/ASN.20253yamgex4, October 2025.<\/em><\/a>\u00a0| DOI: 10.1681\/ASN.20253yamgex4<\/p>\n

<\/em><\/td>\n<\/tr>\n<\/table>\n

\n
\u201cWe are pleased to share this data reinforcing the benefits of long-term treatment with TransCon PTH on renal function,\u201d said Aimee Shu,\u00a0M.D.,\u00a0Executive Vice President of Endocrine & Rare Disease Medical Science and Chief Medical Officer at\u00a0Ascendis Pharma.\u00a0\u201cOur goal at this pre-eminant nephrology meeting is to expand awareness and scientific knowledge of TransCon PTH, the kidney\u2019s role in a healthy parathyroid axis, and the importance of delivering physiological levels of PTH for overall kidney health.\u201d<\/p>\n

TransCon PTH is a prodrug of PTH (1-34), administered once daily, designed to provide active parathyroid hormone (PTH) within the physiological range for 24 hours\/day. TransCon PTH is approved as YORVIPATH\u00ae<\/sup> in the United States, European Union, and European Economic Area as a treatment for adults with hypoparathyroidism.<\/p>\n

\n About Hypoparathyroidism<\/strong>
\n
Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune and idiopathic causes.<\/p>\n

\n About Ascendis Pharma A\/S<\/strong>
\n
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com<\/a> to learn more.<\/p>\n

\n Forward-Looking Statements <\/strong>
\n
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis\u2019 future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis\u2019 plan to present TransCon PTH data during Kidney Week 2025, (ii) Ascendis\u2019 goal to expand awareness of TransCon PTH as an important treatment option, (iii) Ascendis\u2019 ability to apply its TransCon technology platform to make a meaningful difference for patients, and (iv) Ascendis\u2019 application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis\u2019 products and product candidates; unforeseen safety or efficacy results in Ascendis\u2019 development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis\u2019 development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis\u2019 business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis\u2019 ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis\u2019 business in general, see Ascendis\u2019 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis\u2019 other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.<\/p>\n

\n Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and YORVIPATH<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n are trademarks owned by the Ascendis Pharma group. \u00a9 November 2025 Ascendis Pharma A\/S.<\/em>\n <\/p>\n\n\n\n
\n
\n Investor Contacts:
<\/u>
\n <\/strong>Chad Fugere
Ascendis Pharma
ir@ascendispharma.com<\/a><\/p>\n

Patti Bank
ICR Healthcare
+1 (415) 513-1284
patti.bank@icrhealthcare.com<\/a><\/td>\n

\n
\n Media Contact:
<\/u>
\n <\/strong>Melinda Baker
Ascendis Pharma
media@ascendispharma.com<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9. ThursdayNovember 610 a.m. \u2013 12 p.m.Convention CenterExhibit Hall Abstract\u00a0and Poster #TH-PO0227 Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 3-Year Results from the PaTH Forward and PaTHway Trials Gosmanova, Schwarz,Rejnmark et alPresentation on November 6 … <\/p>\n

Continue reading “3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904546","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\n3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9. ThursdayNovember 610 a.m. \u2013 12 p.m.Convention CenterExhibit Hall Abstract\u00a0and Poster #TH-PO0227 Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 3-Year Results from the PaTH Forward and PaTHway Trials Gosmanova, Schwarz,Rejnmark et alPresentation on November 6 … Continue reading "3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T22:11:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025\",\"datePublished\":\"2025-11-03T22:11:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/\"},\"wordCount\":905,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/\",\"name\":\"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=\",\"datePublished\":\"2025-11-03T22:11:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/","og_locale":"en_US","og_type":"article","og_title":"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Market Newsdesk","og_description":"COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A\/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9. ThursdayNovember 610 a.m. \u2013 12 p.m.Convention CenterExhibit Hall Abstract\u00a0and Poster #TH-PO0227 Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 3-Year Results from the PaTH Forward and PaTHway Trials Gosmanova, Schwarz,Rejnmark et alPresentation on November 6 … Continue reading \"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T22:11:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025","datePublished":"2025-11-03T22:11:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/"},"wordCount":905,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/","name":"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=","datePublished":"2025-11-03T22:11:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NzY1MCM3MjQxMjU1IzIwMTEyMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/3-year-renal-data-in-adults-with-hypoparathyroidism-treated-with-transcon-pth-palopegteriparatide-to-be-shared-at-kidney-week-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon\u00ae PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904546"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904546\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}